To improve survival of high-risk neuroblastoma patients, therapeutic strategy should include two essential tasks simultaneously: one to enhance the cytotoxicity of CD4 CTLs, and the other to remove the immunosuppressive TME. This evidence concerns the gene CD4 and neuroblastoma.